VCI Global secures first IPO consultancy deal in 2024

VCI Global has been engaged by a Singapore-based Fin-MedTech Medical Group as its initial public offering, IPO, consultant for its intended IPO on Nasdaq which is expected to be completed in 2024/2025. Under this engagement, VCI Global will provide consultancy services in equity structure and capital market strategy, facilitate engagements of external professionals namely underwriter, auditor and lawyer; assists in regulatory approval and provide recommendations in compliance and internal control matters. VCI Global will receive payment in shares throughout the engagement exercise. Subsequently, the estimated income, to be derived from this consultancy service, is in the range of USD4 million to USD8 million, pending the IPO valuation. “We are honoured that our reputation as an IPO consultant is fast gaining recognition within global business communities where we have been engaged by companies from different countries. With the Medical Group being the latest to engage our services, we are more than happy to share our experience with them, enabling them to have a successful IPO exercise,” said Dato’ Victor Hoo, Group Executive Chairman and Chief Executive Officer of VCI Global.